257 related articles for article (PubMed ID: 28505442)
1. Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects.
Huang Z; Fu J; Zhang Y
J Med Chem; 2017 Sep; 60(18):7617-7635. PubMed ID: 28505442
[TBL] [Abstract][Full Text] [Related]
2. NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001.
Scicinski J; Oronsky B; Ning S; Knox S; Peehl D; Kim MM; Langecker P; Fanger G
Redox Biol; 2015 Dec; 6():1-8. PubMed ID: 26164533
[TBL] [Abstract][Full Text] [Related]
3. Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001.
Oronsky B; Oronsky N; Cabrales P
J Cell Mol Med; 2018 Oct; 22(10):5076-5082. PubMed ID: 30010241
[TBL] [Abstract][Full Text] [Related]
4. Rockets, radiosensitizers, and RRx-001: an origin story part I.
Oronsky B; Scicinski J; Ning S; Peehl D; Oronsky A; Cabrales P; Bednarski M; Knox S
Discov Med; 2016 Mar; 21(115):173-80. PubMed ID: 27115167
[TBL] [Abstract][Full Text] [Related]
5. Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
Oronsky B; Guo X; Wang X; Cabrales P; Sher D; Cannizzo L; Wardle B; Abrouk N; Lybeck M; Caroen S; Oronsky A; Reid TR
J Med Chem; 2021 Jun; 64(11):7261-7271. PubMed ID: 34043360
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide in cancer therapeutics: interaction with cytotoxic chemotherapy.
Hirst D; Robson T
Curr Pharm Des; 2010; 16(4):411-20. PubMed ID: 20236069
[TBL] [Abstract][Full Text] [Related]
7. Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.
Fens MH; Cabrales P; Scicinski J; Larkin SK; Suh JH; Kuypers FA; Oronsky N; Lybeck M; Oronsky A; Oronsky B
Med Oncol; 2016 Aug; 33(8):85. PubMed ID: 27377482
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide: cancer target or anticancer agent?
Mocellin S
Curr Cancer Drug Targets; 2009 Mar; 9(2):214-36. PubMed ID: 19275761
[TBL] [Abstract][Full Text] [Related]
9. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.
Oronsky B; Paulmurugan R; Foygel K; Scicinski J; Knox SJ; Peehl D; Zhao H; Ning S; Cabrales P; Summers TA; Reid TR; Fitch WL; Kim MM; Trepel JB; Lee MJ; Kesari S; Abrouk ND; Day RM; Oronsky A; Ray CM; Carter CA
Expert Opin Investig Drugs; 2017 Jan; 26(1):109-119. PubMed ID: 27935336
[TBL] [Abstract][Full Text] [Related]
10. Controlled Delivery of Nitric Oxide for Cancer Therapy.
Alimoradi H; Greish K; Gamble AB; Giles GI
Pharm Nanotechnol; 2019; 7(4):279-303. PubMed ID: 31595847
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide donors: novel cancer therapeutics (review).
Huerta S; Chilka S; Bonavida B
Int J Oncol; 2008 Nov; 33(5):909-27. PubMed ID: 18949354
[TBL] [Abstract][Full Text] [Related]
12. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
Das DS; Ray A; Das A; Song Y; Tian Z; Oronsky B; Richardson P; Scicinski J; Chauhan D; Anderson KC
Leukemia; 2016 Nov; 30(11):2187-2197. PubMed ID: 27118403
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide donors for prostate and bladder cancers: Current state and challenges.
Seabra AB; Durán N
Eur J Pharmacol; 2018 May; 826():158-168. PubMed ID: 29501865
[TBL] [Abstract][Full Text] [Related]
14. Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19.
Oronsky B; Knox S; Cabrales P; Oronsky A; Reid TR
Semin Oncol; 2020 Oct; 47(5):305-308. PubMed ID: 32718560
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide releasing nanomaterials for cancer treatment: current status and perspectives.
Seabra AB; de Lima R; Calderón M
Curr Top Med Chem; 2015; 15(4):298-308. PubMed ID: 25579351
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
Naimi E; Zhou A; Khalili P; Wiebe LI; Balzarini J; De Clercq E; Knaus EE
J Med Chem; 2003 Mar; 46(6):995-1004. PubMed ID: 12620076
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities.
Mocellin S; Bronte V; Nitti D
Med Res Rev; 2007 May; 27(3):317-52. PubMed ID: 16991100
[TBL] [Abstract][Full Text] [Related]
18. [Nitric oxide and anti-protozoan chemotherapy].
Gradoni L; Ascenzi P
Parassitologia; 2004 Jun; 46(1-2):101-3. PubMed ID: 15305696
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide: state of the art in drug design.
Serafim RA; Primi MC; Trossini GH; Ferreira EI
Curr Med Chem; 2012; 19(3):386-405. PubMed ID: 22335514
[TBL] [Abstract][Full Text] [Related]
20. Nitrite may serve as a combination partner and a biomarker for the anti-cancer activity of RRx-001.
Cirrik S; Ugurel E; Aksu AC; Oronsky B; Cabrales P; Yalcin O
Biorheology; 2019; 56(4):221-235. PubMed ID: 31640080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
